The Arnau de Vilanova University Hospital participates in a new pioneering clinical trial for the treatment of metastatic breast cancer of the triple negative subtype

The treatment of metastatic breast cancer has seen a very significant improvement in survival, although the triple-negative subtype has not yet achieved this benefit. Patients with this profile at the Hospital Universitario Arnau de Vilanova (HUAV) will soon participate in a new clinical trial with drugs that are very active in this stage and help to improve the prognosis of this type of breast cancer.

"This trial is a very important advance for these patients who were still orphans of a more specific treatment with drugs that have demonstrated greater activity in this type of tumour" explained the HUAV physician and researcher of the GREBIC group of the Institute of Biomedical Research of Lleida, Serafín Morales. Today, 19 October, is World Breast Cancer Day.

This new trial will combine treatment with a new drug (sacituzumab govitecam), which has shown a very interesting benefit in these patients after having progressed to previous chemotherapy treatments. As in all clinical trials, it will be up to the medical professionals to determine who can participate in the trial.